NCT06366750: An ongoing trial by Celldex Therapeutics
This trial is ongoing. It must report results 1 year, 1 month from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06366750 |
|---|---|
| Title | A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab (CDX-0159) in Patients With Prurigo Nodularis |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | April 12, 2024 |
| Completion date | Jan. 31, 2026 |
| Required reporting date | Jan. 31, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |